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Lipid signalingPhospholipase D (PLD) has been implicated in many physiological functions, such as chemotaxis and phagocytosis,
as well as pathological functions, such as cancer cell invasion and metastasis. New inhibitors have been described
that hamper the role of PLD in those pathologies but their site of action is not known. We have characterized the
biochemical and biological behavior of the PLD1/2 dual inhibitor 5-Fluoro-2-indolyl des-chlorohalopemide (FIPI),
and the speciﬁc PLD2 inhibitor, N-[2-[1-(3-Fluorophenyl)-4-oxo-1,3,­8-triazaspiro[4.5]dec-8-yl]ethyl]-2-
naphthalenecarboxamide (NFOT), and found that both FIPI and NFOT are mixed-kinetics inhibitors. Mutagenesis
studies indicate that FIPI binds at S757 of PLD2, which is within the HKD2 catalytic site of the enzyme, whereas
NFOTbinds to PLD2 at two different sites, one being at S757/S648 and another to an allosteric site that is a natural
site occupied by PIP2 (R210/R212). This latter site, along with F244/L245/L246, forms a hydrophobic pocket in
the PH domain. The mechanism of action of FIPI is a direct effect on the catalytic site (and as such inhibits
both PLD1 and PLD2 isoforms), whereas PLD2 affects both the catalytic site (orthosteric) and blocks PIP2 binding
to PLD2 (allosteric), which negates the natural enhancing role of PIP2. Moreover, NFOT prevents cell invasion of
cancer cells, which does not occur in cells overexpressing PLD2-F244A/L245A/L246A, or PLD2-R210A/R212A, or
PLD2-S757/S648mutants. This study provides new speciﬁc knowledge of enzyme regulation andmechanisms of
activation and inhibition of PLD2 that are necessary to understand its role in cell signaling and to develop new
inhibitors for cancer cell invasion and metastasis.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Phospholipase D (PLD) is a hydrolytic enzyme that catalyzes the
conversion of phosphatidylcholine (PC) to produce free acid, phospha-
tidic acid (PA), and choline. Phospholipase D belongs to the HKD
superfamily that has one or two “H-x-K-x(4)-D” motifs in its catalytic
site. This HKD motif accounts for the lipase activity of Phospholipase
D. There are 6 isoforms of mammalian PLD, namely, PLD1–6. PLD1
and PLD2 belong to the classical HKD superfamily that possesses
phosphoinositide binding (PX) and pleckstrin homology (PH) domains
with 2 HKDmotifs, while PLD3–6 and bacterial cardiolipin synthase be-
long to the non-classical HKD superfamily that lack PX and PH domains
andmay have 1 or 2 HKDmotifs. The PX and PH domains of PLD are the
major regulatory domains of PLD. However, there are studies showing
the C-terminus of PLD also has binding regions for small GTPases such
as ARF and Rho, which functions in a regulatory role [6,32].andMolecular Biology, Wright
hway, Dayton, OH 45435, USA.
ez-Cambronero).
. This is an open access article underThe PX is a phosphointositide (PI)-binding domain involved in
targeting of proteins to cell membranes. The PX domain was ﬁrst
identiﬁed in p40phox and p47phox of NADPH oxidase and later was
also found inmany PI3 kinases [20,30]. The PH domain is approximately
120 amino acid sequence that occurs in many proteins that are in-
volved in signaling or are constituents of cytoskeleton. This domain
can bind PI lipids within the membrane [28], big subunits of
heterotrimeric G-proteins such as receptor tyrosine and serine/threonine
kinases [29] and protein kinase C [33]. The PLD2-PH domain is known to
interact with phosphoinositide 4,5-bisphosphate (PtdIns (4,5)P2) (PIP2),
and this interaction is important for the intracellular localization of
PLD2 [8,9,23].
The product of its enzymatic reaction carries many of the functions
of PLD in cell signaling and it is involved in cellular signaling and
membrane dynamics in all eukaryotes [12]. Thus, PA binds to ribosomal
S6 kinase (S6K) and leads to subsequent actin polymerization and
chemotaxis, for leukocytes [14]. PA interacts with many other proteins
such as mTOR, Sos [36], Rac and Ras [19]. PA also interacts with Sos
through Grb2 activating the Erk/MAPK pathway [36] culminating in
DNA synthesis [2]. PA serves as a precursor for bioactive lipids such as
LPA and DAG.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Table 1
Table showing list of existing PLD inhibitors, their abbreviations, chemical structure and isoform speciﬁcity. Also mentioned are the IC50 values.
PHOSPHOLIPASE D (PLD) INHIBITORS
IUPAC name Abbrev. name Chemical structure Isoform speciﬁcity
N-[2-[1-(3-Fluorophenyl)-4-oxo-1,3,­8-triazaspiro[4.5]dec-8-yl]ethyl]-
2-naphthalenecarboxamide. [13]
NFOT PLD2 inhibitor
N-[2-(4-oxo-1-phenyl-1,3,8-triazaspiro[4,5]dec-8-yl)ethyl]-2-
naphthalenecarboxamide. [37]
NOPT PLD2 inhibitor
N-[2-[4-(5-chloro-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-
1-piperidinyl]-1-methylethyl]-2-naphthalenecarboxamide.
[37]
NBOD PLD1 inhibitor
(1R,2R)-N-([S]-1-{4-[5-bromo-2-oxo-2,3-dihydro-1H-benzo(d)imidazol-
1-yl]piperidin-1-yl} propan-2-yl)-2- phenylcyclopropanecarboxamide.
[37]
RBPC PLD1 inhibitor
N-[2-[4-(2,3-Dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]ethy]-
5-ﬂuoro-1H-indole-2-carboxamide; other name: 5-Fluoro-2-Indolyl des-
Chlorohalopemide. [26]
FIPI Dual (PLD1 and PLD2)
inhibitor
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of PLD2 expression were observed in patients with colorectal cancer
[18,21]. A polymorphism in PLD2 1814 C ➔ T causing a mutation,
Ile577Thr, was predominant in colorectal cancer patients, but this poly-
morphism did not affect PLD activity [31]. Previous studies have shown
that inhibiting PLD1 in the tumor microenvironment by FIPI dampens
metastasis and angiogenesis [1]. On the other hand, involvement of
PLD2 in tumor metastasis and invasion was also reported, wherein, it
was shown that NOPT (a speciﬁc PLD2 inhibitor) inhibited tumor
metastasis and cell invasion in xenograft mice models [7].
Based on the large array of functionalities ascribed to PLD, it is no
surprise that inhibitors are necessary to probe this ﬁeld further. New
and powerful PLD inhibitors have been synthesized that in many cases
are derivatives of halopemide (Table 1) [1,13,17,24,25]. These inhibitors
show greater inhibition in vitro, while their bioavailability in vivo is
reduced due to the properties of the drug, including hydrophobicity
and solubility. Monovich et al. showed that the half-life of FIPI in vivo
is 5.5 hours and the bioavailability is only 18% [17].
To date, there is no clear site of action of these speciﬁc small-molecule
inhibitors on PLD2 and/or their mechanism of action. This study reports
that the PLD2 inhibitor NFOT uses an allosteric site, which overlaps withPIP2 binding sites of the PH domain, to target its activity. The importance
of this is that knowledge about the mechanism and kinetics of the
existing inhibitors will help in developing more potent PLD inhibitors
to be used in pathological conditions.2. Materials and methods
2.1. Materials
The COS-7, African blackmonkey kidney ﬁbroblasts were purchased
from ATCC. COS-7 culture medium Dulbecco’s modiﬁed eagle medium
(DMEM), Fetal Bovine Serum and TransfectaGRO were obtained from
Corning Cellgro® (Manassas, VA). Lipofectamine, Plus, and EGF were
purchased from Invitrogen (Carslbad, CA). 3[H]- butanol was obtained
from Perkin Elmer (Waltham, MA). All the phospholipids required for
lipase enzyme activity assays including PC8 and PIP2 were purchased
from Avanti Polar Lipids. Matrigel inserts were purchased from BD
(Franklin Lakes, NJ). Hematoxylin stain was obtained from Ricca
(Arlington, TX). Phospholipase D (PLD) inhibitors were obtained from
Cayman Chemicals, Avanti polar lipids and Tocris biosciences.
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COS-7 cells were cultured and sub-cultured in DMEMwith 10% FBS,
50 U/ml Penicillin, 50 U/ml Streptamycin, and 50 μg/ml Gentamycin at
37 °C temperature and 5% carbon-dioxide in a CO2 incubator. Cells
were split at 80% conﬂuence. The cells were transfected at 60% conﬂu-
ence per well with plasmids ranging from 1–6 μg of DNA, using 6 μl
Lipofectamine and 6 μl Plus diluted in 600 μl TransfectaGRO. Sterile
glass culture tubes housed each aliquoted liposome solution
(DNA + Lipid complex) prior to transferring the solution into 6-well
plates of cells containing 1 ml of TransfectaGRO. The transfection mix
was allowed for 3 hours and then themedia was aspirated and changed
to fresh complete DMEM. Transfection was allowed to go for 48 hours.
2.3. Phospholipase activity assay
PLD2 was processed for lipase activity as mentioned in refs. [3,7,10,
14,15,34]. Brieﬂy, the assay was performed in liposomes of 1,2-
dioctanoyl-sn-glycero-3-phosphocholine (PC8) and [3H]-butanol. The
following reagents (ﬁnal concentrations): 3.5 mm PC8 phospholipid,
45 mm HEPES, pH 7.8, and 1.0 μCi of n-[3H]-butanol were added in a
liposome form as indicated in ref. [15]. Samples were incubated for
20 min at 30 °C with continuous shaking. The addition of 0.3 ml of ice-
cold chloroform/methanol (1:2) stopped the reactions. Lipids were iso-
lated, dried (under N2), and resuspended in chloroform:methanol (9:1)
and then spotted on thin-layer chromatography plates along with
phospholipid controls 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine
(p-ethanol) and 1,2-dipalmitoyl-sn-glycero-3-phosphobutanol
(p-butanol) (Avanti polar lipids, Inc., AL). The amount of [3H]-
phosphatidylbutanol ([3H]-PBut) that co-migrated with PBut stan-
dards was measured by scintillation spectrometry. Whole cells were
assayed quite similar to the lysates, except that the cellswere ﬁrst treat-
ed with inhibitor for 25 min at 37 °C. Followed by inhibitor treatment,
lysates were prepared and subjected to lipase activity assay.
2.4. Generation of puriﬁed PLD2
A baculovirus expression system was used for the overexpression
and subsequent puriﬁcation of recombinant, full-length PLD2 for use
in certain enzymatic reactions. Brieﬂy, the PLD2-WT gene and the
Bsu36I-digested BacPAK5 viral DNA were co-transfected into Sf21 in-
sect cells in separate reactions, which rescued the very large viral DNA
and effectively transferred the PLD2 gene into the AcMNPV genome.
PLD2 baculoviral stock that overexpressed PLD2-WT was selected and
used to infect Sf21 insect cells for further overexpression of PLD2 and
enrichment of PLD2 using a TALON matrix, as described in ref. [4].
2.5. Enzyme inhibition assay
Cells were cultured and transfected with PLD1 or PLD2, 48 h post-
transfection, cells were starved for 2 h, stimulated with EGF (3 nM),
and cells lysates were prepared. For some experiments (named
“whole cells”), whole cells were treated with inhibitors prior making
lysates, or cell lysates were treated directly with the inhibitors
(named “lysates”). At any case, the treatment was 300 nM (unless oth-
erwise indicated) PLD1 inhibitor (NBOD), PLD2 (NFOT) inhibitor and
dual inhibitor (FIPI) for 25 min. After treatment with the inhibitor, the
lysates were prepared and taken to lipase activity assay as mentioned
above, but with increasing concentrations of PC8, which is the substrate
of PLD. The phospholipase activity of the enzyme was measured by
measuring the radioactivity in a scintillation counter.
2.6. Western blotting
Lysates were prepares in the desired volume of Special lysis buffer
(50 mM HEPES, pH 7.2, 100 μM Na3VO4, 0.1% Triton X-100, and1 mg/ml each of protease inhibitors (aprotonin and leupeptin) and
then sonicated. The BIO-RAD protein estimation assay was utilized to
determine the protein concentration and to normalize among prepara-
tions to ensure equal protein content per reaction. The desired concen-
tration of protein was loaded into the wells of SDS–PAGE gels along
with a molecular weight marker. These gels were then transferred for
1 h onto PVDF membrane, blocked for 45 min at room temperature
with 1% BSAwith TBS, 0.2% Tween 20 (TBS-T), and probedwith primary
antibody overnight. The blotswere thenwashedwith TBS-T and probed
with secondary antibody conjugated to horseradish peroxidase (HRP)
and detected on x-rayﬁlmswith the help of ECLwestern blotting detec-
tion reagents from GE Health Care (Fairﬁeld, CT). The Kodak Gel Logic
software used to perform densitometry on western blots, which
consists of quantifying the band of the protein of interest versus the
band of the actin-loading control.
2.7. Cell migration and cell invasion
Adherent cells were detached using 25% Trypsin/EDTA or a non-
enzymatic cell dissociation buffer for COS-7 or RAW264.7 cells, respective-
ly. A hemocytometer was used to count cells, and trypan blue exclusion
was used to determine cell viability. 24-well plates and Transwell inserts
were pre-wetted with DMEM containing 0.5% BSA. Cell concentration
was adjusted to 5 × 104 cells per 400 μl of DMEM containing 0.5% BSA
per insert. 600 μl of DMEM containing 5% BSA was added to the bottom
of the well prior to placing the cells and insert in the well. Three
nanomolar EGF for COS-7 cells or 3 nM M-CSF for RAW264.7 cells were
used as chemoattractants, respectively. The murine macrophage cells
were allowed to migrate for 3.5 h and COS-7 cells migrated for 1 h at
37 °C, 5% CO2. Afterward, insertswere removed and cells that hadmigrat-
ed to the bottomwere ﬁxedwith 4% paraformaldehyde in eachwell. Cells
that migrated to the bottom were then allowed to settle and adhere be-
fore being counted. Cellswere then countedusing an invertedmicroscope
at 20×. The average numbers of 6 counts per well were counted and
statistics performed. Cell invasion was conducted using Matrigel inserts.
2.8. Prediction of full-length PLD2 structure: homology modeling
Full-length PLD2 structure model was obtained as explained in ref.
[16]. Brieﬂy, the primary sequence of PLD2was submitted to the protein
prediction servers, I-TASSER (Iterative threading assembly reﬁnement)
[35] and Phyre 2 (protein homology/analogy recognition engine) [11]
servers. The molecular modeling and visualization of the structure
modelwas performedusing the Swiss PDB viewer (SPDBV) [5].Multiple
candidate structureswere analyzed to select the ﬁnal structure. By visu-
al inspection, we concluded the PLD2model predicted by Phyre2 server
meets most of the set criteria that were based on the experimental
ﬁndings from the literature. However, the model was still not entirely
energetically favorable as certain amino acid conformations were
not reasonable. These issues were ﬁxed by manually perturbing
the structure using SPDBV and energy minimizing the resulting
structure(s) using steepest descent and conjugate gradient methods.
Finally, the complete 3D model was energy minimized which resulted
in amodel, whichwas energetically favorable and consistentwith exper-
imental criteria.
2.9. Molecular docking
The computer-simulated docking studies were performed using
AutoDock Vina [27], which allows rotation about ligand in order to
have ﬂexible/rotatable bonds. Dockingwith AutoDock Vina starts by de-
ﬁning a search space or binding site in a restricted region of the protein.
In order to dock the small-molecule inhibitors with our PLD2 structure
model, a receptor grid was generated including the two catalytic histi-
dines (442 and 756) in our 3Dmodel. The resulting ligand conformation
was further visualized using the PyMOL. Regarding to the structures of
264 R. Ganesan et al. / Biochimica et Biophysica Acta 1851 (2015) 261–272the inhibitors, structural information was take from PubChem or Cay-
man chemicals and 3D models built in used SPDBV Swiss Protein Data
Bank Viewer.2.10. Statistical Analysis
Data are presented as the mean ± SEM. The difference between
means was assessed by the single-factor analysis of variance (ANOVA)
test. Probability of p b 0.05 was considered to indicate a signiﬁcant
difference.E
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3.1. Characterizing the existing PLD inhibitors
The goal of this study is to obtain information from the existing PLD
inhibitors regarding the type of the inhibitors and the site of their action.
This will further allow the development of speciﬁc and efﬁcient inhibi-
tors. PLD inhibitors available are either PLD1 speciﬁc or PLD2 speciﬁc
or dual inhibitors. However, the type of these inhibitors as in whether
they are competitive or non-competitive or mixed, is not clear. There-
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269R. Ganesan et al. / Biochimica et Biophysica Acta 1851 (2015) 261–272and FIPI (EC50 ~ 8–9 nM). FIPI affected also PLD1 (EC50 ~ 7–10 nM). In
all cases, endogenous PLD activity was also inhibited. The results in
Fig. 1 indicate that NFOT and FIPI are efﬁcient, and hence these two
inhibitors were pursued for all the subsequent experiments of this
study that focus on the PLD2 isoform.
3.2. FIPI and NFOT are mixed-kinetics inhibitors (affect both Vmax and Km)
FIPI’s kinetics have been studied in ref. [26]), and we intended to as-
certain the biochemical and biological behavior of FIPI and NOPT in our
experiment systems. First, in order to determine the optimal time for
maximal lipase activity and maximum effect of the inhibitor, a time
course of the lipase assay was performed in the absence or presence of
NFOT or FIPI. These experiments were performed with both recombi-
nant protein and the cell lysates overexpressing PLD2. Recombinant
PLD2 protein was puriﬁed as mentioned in ref. [4]. Fig. 2A shows the
presence of PLD2 in all the fractions during puriﬁcation process. Results
presented in Fig. 2B and C indicate linearity and all the subsequent
experiments measuring lipase activity were performed for 15 min.
We used two different approaches in order to determine if the type
of inhibition exerted by FIPI or NFOT. In the ﬁrst approach, increasing
concentrations of the puriﬁed recombinant PLD2 was not treated or
treated with 300 nM FIPI or NFOT and a ﬁxed concentration of the sub-
strate PC (3.5 mM) was used to perform lipase assay (Fig. 2D). In the
second approach, a ﬁxed concentration of recombinant puriﬁed PLD2
was not treated or treated with 300 nM FIPI or NFOT and the lipase as-
says were performed with increasing concentrations of PC (Fig. 2D,
Michaelis–Menten plot). Results presented in Fig. 2, where PLD activity
was regained (albeit not totally) with increasing concentrations of en-
zyme (Fig. 2C) or substrate (Fig. 2D), indicate that NFOT is a competitive
inhibitor whereas FIPI was not totally competed off by the enzyme sub-
strate at the concentrations used in these experiments. A Lineweaver–
Burke plot (Fig. 2F) indicates that both FIPI and NFOT increase the Km
while decreasing the Vmax, indicating a mixed-type inhibition. Further,
a second line could be plotted in the case of NFOT experimental points
if one considers high concentration of substrate (N10 mM). This is
indicated by dashed lines in Fig. 2F and could be the ﬁrst evidence
that NFOT could have two sites of inhibition on PLD2.
3.3. PLD2 inhibition in the presence of PIP2
Next,wewanted to determine the effect of PIP2, a knownpositive ef-
fector of PLD2 on the action of inhibitors. Regarding the PIP2 binding to
proteins, PIP2 bindingmotifs in various proteins are notwell deﬁned but
generally are comprised of clusters of basic and aromatic amino acid
residues. Sciorra et al. [22,23] demonstrated that R237 and W238 in
the PH domain and R553 and R557 in the C-terminus of PLD2 are the
binding sites for PIP2 on PLD2. In addition, we recently identiﬁed anoth-
er binding site in the PH domain of PLD2, which consists of R210 and
R212 [16]. All these studies together suggest that there is a possibility
that multiple PIP2 molecules can bind the protein at the same time.
Recombinant PLD2 was untreated or treated with 300 nM FIPI or
NFOT, after which the samples were subjected to lipase assay with in-
creasing concentrations of PIP2 and a ﬁxed concentration of the sub-
strate PC8. Results from vehicle treated sample (black line) suggest
that PIP2 exerts both a positive effect and a negative effect on PLD2
(Fig. 3A). A positive effect was observed at low (~100 nM) concentra-
tion of PIP2, whereas at higher concentrations the activity returned to
basal level. Even with increasing concentrations of PIP2, FIPI inhibited
the enzyme. However in the presence of NFOT the enzyme activity
was regained back with increasing concentrations of PIP2 suggesting
that PIP2 and the inhibitor might have overlapping interaction sites.Fig. 5.Dose-dependent effect of NFOT on the selectedmutants. Mutants (A) H158Q, Y165F and
HKDwere treated with increasing concentrations of NFOT and subjected to lipase assay. F244N
trations of NFOT. Panels E and F show the ribbon (E) and surface (F) of NFOT biding to the alloOverall, this suggests that PLD2 inhibition by small-molecule compound
NFOT is due to its binding to the natural site used by PLD-activator PIP2
in addition to the catalytic site. Thus, NFOT causes both a competitive
and allosteric inhibition. Modeling of putative sites of FIPI or NFOT
with PLD2 3D model structure were performed using Autodock vina.
The panels show the 3-D modeling of NFOT and FIPI as binding in the
vicinity of the PLD catalytic center. In modeling, rotation was allowed
between bonds in small molecules NFOT and FIPI.3.4. The inhibitor’s site on PLD2
Most or all of the existing PLD inhibitors are hydrophobic in nature
that makes them highly insoluble in polar solvents, because of which
it is very difﬁcult to be able to use them in animal models. Also, the
mechanism or site of action of these inhibitors is not clearly understood.
Therefore we propose that elucidating themechanism of action of these
small-molecule inhibitors of PLD is essential in order to design more
efﬁcient, speciﬁc and potent inhibitors.
Our approach was to create mutants and screen them to determine
the effect of the inhibitors on these mutants. We made the mutations
in such a way that hydrophobic residues were mutated into less hydro-
phobic residues and charged amino acids such as arginine were mutat-
ed toneutral amino acids. The rationale behind this is to determine if the
inhibitors require hydrophobic and charged amino acids to interact
with PLD2. A battery of PLDmutants (Fig. 4A) in the PX, PH, and around
HKD regions was designed in order to screen the resistance against in-
hibitors. Hydrophobic residues such as leucine, arginine, and tyrosine
were mutated to less hydrophobic alanine. Protein expression of the
PLD2 mutants is shown in Fig. 4B. All the mutants were compared
with PLD2-WT in terms of the lipase activity. Mutants with 75% or
more lipase activity (shown in red bars) relative to WT, and those
were considered for subsequent experiments (Fig. 4C-E, 2nd dashed
line).
Fig. 4 demonstrates that FIPI inhibited most of the mutants, except
that PLD2-S757A was resistant to 300 nM FIPI. On the other hand,
PLD2-H158Q, Y165F, and L173A in the PX domain, PLD2-R210/212A
and PLD2-F244N/L245/L246A in the PH domain and PLD2-S648A and
S757A in and around the HKD region demonstrated resistance against
300 nMNFOT (Fig. 4C–E). To conﬁrm the same, these resistant mutants
were subjected to increasing concentrations of NFOT (Fig. 5) or FIPI
(data not shown). The results suggest that PLD2-R210A/R212A, PLD2-
F244N/L245/L246A, PLD2-S648A, and PLD2-S757A are partially resis-
tant to inhibition over a range of inhibitor concentrations of NFOT
(Fig. 5A-D). Fig. 5E,F show the 3-D modeling of NFOT binding to the
allosteric site in the PLD 244–246 region.3.5. Functional relevance of the inhibitor resistant mutants
In order to determine the functional relevance of the inhibitor
resistant mutants in Fig. 4 (red bars), we performed cell migration of
ﬁbroblasts (COS-7 cells) and cell invasion assays of breast cancer cells
(MDA-MB-231) in the absence or presence of 300 nM, 700 nM FIPI or
NFOT. The results presented in Fig. 6A and B indicate that these
mutations are not affecting PLD2-mediated cell migration as well as
invasion. In addition, the mutants that were observed to be resistant
in Fig. 4 such as PLD2-R210A/R212A, PLD2-F244N/L245/L246A, PLD2-
S648A, and PLD2-S757A are also resistant to inhibition in terms of cell
migration and cell invasion and PLD2-Y165F was found to be partially
resistant to inhibition in terms of chemotaxis, explaining the functional
relevance.L173A in the PX, (B) R210/212A and F244N/L245/L246A in the PH and (C and D) S648 near
/L245/L246A and S648A were found to be partially resistant even with increasing concen-
steric site in the PLD enzyme. Colored in purple are the hydrophobic residues.
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Our ﬁndings suggest that S757 is a target for FIPI inhibition and that
S757/S648 as well as F244, L245, and L246 are the target of NFOT action
and thatmutating these key amino acid(s) results in partial resistance of
the enzyme towards the inhibitor. Also, this is the ﬁrst study where we
have elucidated the kinetics of known PLD2 inhibitors. Lineweaver–
Burke (LB) plot (Fig. 2F) shows that FIPI and NFOT inhibit PLD by
increasing the Km and decreasing Vmax values, which therefore, might
result in amixed inhibition.Mixed inhibition suggests a wide repertoire
of binding sites on PLD2, includingboth catalytic and regulatory regions.
However, mixed inhibition of PLD2 by FIPI and NFOT does not suggest
anything speciﬁc about their binding site on PLD2. To explore the site
of action, we designed a battery of mutants within the PX, PH, and
HKD regions of PLD2.
The data presented here suggests that FIPI is hard to be competed
off by the substrate, perhaps because it may have a component ofirreversible inhibitor while NFOT can be competed off easily (but not
completely) by NFOT. The mutants, PLD2-F244N/L245/L246A, PLD2-
R210A/R212A, and S648A are partially resistant to inhibition by NFOT
(Fig. 5). Thus, the binding site of the inhibitor FIPI might be in the HKD re-
gion, which is suggestive of covalent modiﬁcations FIPI canmake to PLD2.
On the other hand, bothHKD regions aswell as PIP2 binding regionsmight
be the sites for NFOT’s action. The fact that PLD2-F244N/L245/L246A is
NFOT resistant suggests that NFOT might bind to the regulatory regions
of PLD2, possibly affecting the binding of positive regulators like PIP2
(Fig. 3). The amino acids F244, L245, and L246 are in near vicinity to the
PIP2 binding region R210 and R212 [16], suggesting that NFOT interaction
overlap with PIP2 binding to PLD2. Moreover, our data demonstrates that
higher concentrations of PIP2 can rescue PLD2 fromNFOT’s inhibition sug-
gesting that NFOT does bind to the site occupied by PIP2. NFOT is a speciﬁc
PLD2 inhibitor and hence does not affect PLD1 (Fig. 1D). Based on the fact
that FIPI is a dual inhibitor and our ﬁndings that it might be irreversibly
inhibiting PLD2, we speculate that FIPI imparts a similar mechanism of
PX
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HKD-II
PCho PA + Cho
 Catalytic site
   (FIPI and 
     NFOT)
S648HK
D-I
S757
L24
4/L2
45
     /
L24
6
PIP2
Substrate (PCho) 
FIPI (one-site inhibitor)
NFOT (two-site inhibitor)
+
Fig. 7. A model showing the mechanism of action of FIPI and NFOT. FIPI (a dual, PLD1/
PLD2-inibitro and NFOT (a PLD2-speciﬁc inhibitor) act at a site in the vicinity of the lipase
catalytic site. In addition, NOFT is both a competitive and allosteric inhibitor. As indicated
in this study, the possible sites of action of NFOT are F244, L245, and L246 (allosteric) in
the PH region (PIP2 binding site) and S757/S648 (orthosteric) near the HKD region, while
the site of action of FIPI is S648.
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HKD regions in the PLDmolecule. FIPImight inhibit PLD1 activity irrevers-
ibly by certain covalent modiﬁcations (perhaps mediated by its ﬂuoride
moiety) not allowing complete recovery of PLD activity and its role in sev-
eral physiological functions. FIPI interacts with the catalytic residues and
thus imparts inhibition on both PLD1 and PLD2, which we speculate
could be in part a result of a covalentmodiﬁcation of the enzymemolecule
by the action of FIPI’s ﬂuoridemoiety.Wewould expect a similar action of
FIPI on PLD1, since it is a dual inhibitor andmight interact with conserved
regions on the PLD molecule.
Thus, we have developed a working model with this study showing
the effect of inhibitors and the type of inhibition on PLD2 by FIPI or NFOT
(Fig. 7). Themodel shows that NFOT binds to an allosteric sitewith high
afﬁnity and with comparatively low afﬁnity to an orthosteric site (the
catlytic site) on PLD2, while FIPI might cause an irreversible inhibition
possibly by covalent modiﬁcation of the catalytic site.
From our ﬁndings on the action of the two PLD2 inhibitors, FIPI and
NFOT, one could say the two have different modes of action. FIPI could
possibly act by modifying the enzyme (Figs. 1, 2E), whereas NFOT inter-
acts at both the catalytic and allosteric sites suggesting two sites of action.
The two sites for action of NFOT could possibly be accounted for by its
structure wherein the ﬂuoride possibly interacts at the catalytic site and
the two benzyl rings interact at the allosteric site. Another ﬁnding from
our study that would correlate with FIPI action is that the inhibition of
PLD2 signiﬁcantly higher thanPLD1byNBOD that alsohas aﬂuoridemoi-
ety. At any case, this study provides new speciﬁc knowledge of enzyme
regulation and mechanisms of activation and inhibition of PLD2 that are
necessary to understand its role in cell signaling and to develop more
powerful inhibitors for cancer cell invasion and metastasis.References
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